Search
Brasofensine
go.drugbank.com/drugs/DB04857ExperimentalIn November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.
NCX 950
go.drugbank.com/drugs/DB05849ExperimentalNCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.
Penimepicycline
go.drugbank.com/drugs/DB13264ExperimentalIn the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans [L5620]. … It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].
Konjac mannan
go.drugbank.com/drugs/DB14963InvestigationalKonjac mannan is under investigation in clinical trial NCT01709955 (The Effects of Glucomannan on Weight Loss).
JTC-801 free base
go.drugbank.com/drugs/DB17033ExperimentalAn antagonist of nociceptin receptor and analgesic agent, evaluated for its use in cancer treatment.[A253027]
Synonyms: Benzamide, n-(4-amino-2-methyl-6-quinolinyl)-2-((4-ethylphenoxy)methyl)-Diaminopyrimidine oxide
go.drugbank.com/drugs/DB18756ApprovedDiaminopyrimidine oxide is a compound similar to [minoxidil] which is used to aid in hair growth.
Synonyms: 2,4-diaminopyrimidine 3-n-oxideIsoxicam
go.drugbank.com/drugs/DB08942ApprovedWithdrawnIsoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.
Serabelisib
go.drugbank.com/drugs/DB14935Investigationalof TAK-117 (MLN1117) in Healthy Participants). … Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics
Adipiplon
go.drugbank.com/drugs/DB06579InvestigationalAdipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.
AI-128
go.drugbank.com/drugs/DB05841ExperimentalAI-128 is the first human demonstration of sustained release drug administration in the lung. … AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.